ImmunoGen Inc. has taken over the number one spot on the list of the state’s largest locally-owned cancer drug developers as ranked by market cap, but as CEO Dan Junius acknowledges, “it was an ugly way to get there.” The 32-year-old Waltham biotech was number two on the list until last week, when Ariad Pharmaceuticals saw a 75 percent stock crash following an FDA-mandated halt in enrollment in a late-stage trial of its sole product on the market - leukemia drug Iclusig - over safety concerns.
Help employers find you! Check out all the jobs and post your resume.
